EA202190798A1 - Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов - Google Patents

Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов

Info

Publication number
EA202190798A1
EA202190798A1 EA202190798A EA202190798A EA202190798A1 EA 202190798 A1 EA202190798 A1 EA 202190798A1 EA 202190798 A EA202190798 A EA 202190798A EA 202190798 A EA202190798 A EA 202190798A EA 202190798 A1 EA202190798 A1 EA 202190798A1
Authority
EA
Eurasian Patent Office
Prior art keywords
rotameric
complexes
isomers
thiones
dithiol
Prior art date
Application number
EA202190798A
Other languages
English (en)
Inventor
Боми Фрамроце
Original Assignee
ЭсТи АйПи ХОЛДИНГ АГ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭсТи АйПи ХОЛДИНГ АГ filed Critical ЭсТи АйПи ХОЛДИНГ АГ
Publication of EA202190798A1 publication Critical patent/EA202190798A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Настоящее изобретение предусматривает, помимо прочего, ротамерные изомеры 4-алкил-5-гетероарил-3H-1,2-дитиол-3-тионов, комплексы таких изомеров, в которых отдельная ротамерная форма получена стабилизацией, и композиции, содержащие избыток отдельного ротамера (ротамерный избыток) в виде стабилизированного комплекса. Изобретение также относится к способам изготовления и применения таких ротамеров и комплексов, включая способы лечения пациента-человека или пациента-животного с помощью таких ротамеров или их комплексов, например, для предотвращения, лечения или уменьшения симптомов различных заболеваний, таких как воспаление слизистой оболочки, и/или обеспечения защиты от окислительного повреждения в различных органах и тканях в медицинских целях.
EA202190798A 2018-09-18 2019-09-17 Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов EA202190798A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862732867P 2018-09-18 2018-09-18
PCT/IB2019/001138 WO2020058767A1 (en) 2018-09-18 2019-09-17 Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2- dithiole-3-thiones

Publications (1)

Publication Number Publication Date
EA202190798A1 true EA202190798A1 (ru) 2021-09-10

Family

ID=69024428

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202190798A EA202190798A1 (ru) 2018-09-18 2019-09-17 Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов

Country Status (14)

Country Link
US (1) US20210206751A1 (ru)
EP (1) EP3853223A1 (ru)
JP (1) JP7514841B2 (ru)
KR (1) KR20210061390A (ru)
CN (2) CN113166127A (ru)
AU (1) AU2019341666A1 (ru)
BR (1) BR112021005010A2 (ru)
CA (1) CA3113169A1 (ru)
EA (1) EA202190798A1 (ru)
IL (1) IL281598A (ru)
MX (1) MX2021003123A (ru)
SG (1) SG11202102653WA (ru)
WO (1) WO2020058767A1 (ru)
ZA (1) ZA202102412B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021186244A1 (en) * 2020-03-16 2021-09-23 St Ip Holding Ag Rotomeric isomers of 4-alkyl-5-heteroaryl-3h-1,2-dithiole-3-thiones
DE202023001038U1 (de) 2023-05-10 2023-06-16 Rainer Teutenberg Ballistisch und akustisch wirksame Bekleidung für Schießanlagen

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3156369A (en) 1962-09-19 1964-11-10 Ethicon Inc Bicameral container
IT1292677B1 (it) 1997-02-28 1999-02-11 Bormioli Metalplast Spa Confezione per mantenere separati dei prodotti prima dell'uso.
TW200640898A (en) * 2005-02-24 2006-12-01 Solvay Pharm Bv Anethole dithiolethione and other dithiolethiones for the treatment of conditions associated with dysfunction of monoamine neurotransmission
MX2007015063A (es) 2005-07-15 2008-01-28 Bormioli Rocco & Figlio Spa Un deposito con un cortador para sustancias que seran mezcladas con liquidos al momento de uso, en particular para contenedores de una sola dosis.
WO2007121356A2 (en) * 2006-04-13 2007-10-25 Accu-Break Technologies Method of treatment with predictably breakable pharmaceutical tablets
GB0704718D0 (en) * 2007-03-12 2007-04-18 Prendergast Patrick T Compounds and methods for preventing and treating mucositis
ES2527604T3 (es) 2010-02-16 2015-01-27 Teva Branded Pharmaceutical Products R & D, Inc. Una composición farmacéutica inhalable
NZ722952A (en) 2012-02-28 2018-12-21 Iceutica Holdings Inc Inhalable pharmaceutical compositions
JP2016519123A (ja) 2013-04-29 2016-06-30 サノフィ・ソシエテ・アノニム 吸入可能な医薬組成物およびそれらを収容した吸入器デバイス
WO2016207914A2 (en) 2015-06-25 2016-12-29 St Ip Holding Ag Methods for preparing oltipraz
CN105327337A (zh) * 2015-10-30 2016-02-17 中国人民解放军96617部队 抗辐射防龋消炎口腔制剂
WO2018047013A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same
WO2018047002A1 (en) * 2016-09-12 2018-03-15 St Ip Holding Ag Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1.2-dithiole-3-thione, taste-modified formulations, and methods of making and using same

Also Published As

Publication number Publication date
US20210206751A1 (en) 2021-07-08
JP2022501424A (ja) 2022-01-06
IL281598A (en) 2021-05-31
WO2020058767A1 (en) 2020-03-26
CA3113169A1 (en) 2020-03-26
AU2019341666A1 (en) 2021-05-13
ZA202102412B (en) 2024-08-28
MX2021003123A (es) 2021-08-11
EP3853223A1 (en) 2021-07-28
JP7514841B2 (ja) 2024-07-11
WO2020058767A4 (en) 2020-06-04
KR20210061390A (ko) 2021-05-27
SG11202102653WA (en) 2021-04-29
CN113694068A (zh) 2021-11-26
BR112021005010A2 (pt) 2021-06-08
CN113166127A (zh) 2021-07-23

Similar Documents

Publication Publication Date Title
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
EA201991894A1 (ru) ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ
EA202193111A1 (ru) Композиции и способы для лечения рака
MX2024002989A (es) Formulaciones de 4-(7-hidroxi-2-isopropil-4-oxo-4h-quinazolin-3-il )-benzonitrilo.
UY38986A (es) Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
EA202190798A1 (ru) Ротамерные изомеры 4-алкил-5-гетероарил-3h-1,2-дитиол-3-тионов
MX2018008903A (es) COMPOSICIONES Y METODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA MODULAR AUTOFAGIA Y LIPOFAGIA.
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
CL2023002549A1 (es) Ciertos compuestos de pladienolida y métodos de uso (divisional).
MX2020013692A (es) Compuestos de pirazol e imidazol para la inhibicion de il-17 y rorgamma.
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202090705A1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
MX2019013562A (es) Compuestos de anilina heteroaromatica o fusionados para el tratamiento de trastornos dermicos.
MX2021015796A (es) Composiciones y metodos para tratar enfermedades oculares.
EA202190751A1 (ru) Способы лечения миелопролиферативных расстройств
CR20240104A (es) Células NK derivadas de la placenta como senolítico para usos terapéuticos y otros.
EA202091647A1 (ru) Соединения, композиции и способы лечения заболеваний, связанных с ацидозными или гипоксическими пораженными тканями
BR112022005980A2 (pt) Método para prevenir e/ou tratar declínio cognitivo em um sujeito cognitivamente saudável, composto, e, uso de um composto
MX2022014888A (es) Propanodioles mononitrosilados y bisnitrosilados para su uso terapéutico.
MX2024004398A (es) Peptidos y fragmentos para tratar diabetes y enfermedades metabolicas asociadas.